Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Non-Current Liabilities (2016 - 2025)

Collegium Pharmaceutical (COLL) has 6 years of Total Non-Current Liabilities data on record, last reported at $1.3 billion in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 4.6% year-over-year to $1.3 billion; the TTM value through Sep 2025 reached $1.3 billion, down 4.6%, while the annual FY2024 figure was $1.4 billion, 51.24% up from the prior year.
  • Total Non-Current Liabilities reached $1.3 billion in Q3 2025 per COLL's latest filing, down from $1.4 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.4 billion in Q4 2024 and bottomed at $947.9 million in Q4 2023.
  • Average Total Non-Current Liabilities over 3 years is $1.3 billion, with a median of $1.4 billion recorded in 2025.
  • Peak YoY movement for Total Non-Current Liabilities: soared 51.24% in 2024, then dropped 4.6% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $947.9 million in 2023, then skyrocketed by 51.24% to $1.4 billion in 2024, then fell by 7.05% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $1.3 billion in Q3 2025, $1.4 billion in Q2 2025, and $1.4 billion in Q1 2025.